Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.44 |
| ▸ | TPI1 | P60174 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL875410 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1TPI1PPARD | |
| Ethylene SCHEMBL10780295 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1TPI1PPARD | |
| Ethylene SCHEMBL7647509 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1TPI1PPARD | |
| SCHEMBL26209 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL2329731 | 0.92 | — | — | |
| Water SCHEMBL9650575 | 0.92 | — | — | |
| SCHEMBL5144314 | 0.92 | — | — | |
| Phosphoric Acid SCHEMBL22576854 | 0.92 | LPAR3 (0.46) | LPAR3LPAR2LPAR1TPI1PPARD | |
| SCHEMBL8740020 | 0.92 | — | — | |
| SCHEMBL29151935 | 0.92 | LPAR3 (0.46) | LPAR3LPAR2LPAR1TPI1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | IKARIA THERAPEUTICS LLC | 2015-01-01 | — | — | US | disclosed |
| US-8871189-B2 | MMP-targeted therapeutic and/or diagnostic nanocarriers | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2785635-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | Mallinckrodt LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013082389-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | MALLINCKRODT LLC (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | LPAR3 767/4885LPAR2 916/4885LPAR1 1001/4885 |
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | LPAR3 767/4885LPAR2 916/4885LPAR1 1001/4885 |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | EPHA2, ANXA6, SLC10A1 | LPAR3 448/4885LPAR2 649/4885LPAR1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.